Comparative Pharmacology
Head-to-head clinical analysis: CONEXXENCE versus GILDESS 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONEXXENCE versus GILDESS 1 20.
CONEXXENCE vs GILDESS 1/20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic GnRH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
GILDESS 1/20 is a combination oral contraceptive containing ethinyl estradiol (an estrogen) and gestodene (a progestin). Its primary mechanism is inhibition of ovulation via suppression of gonadotropin-releasing hormone (GnRH), leading to reduced follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion. Additionally, it alters cervical mucus (increasing viscosity to impede sperm penetration) and endometrial structure (rendering it unsuitable for implantation).
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
One tablet orally daily, each containing 20 mcg ethinyl estradiol and 150 mcg desogestrel.
None Documented
None Documented
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Ethinylestradiol: terminal half-life ~13-27 hours (mean 17 hours). Gestodene: terminal half-life ~12-15 hours. Steady-state reached within 5-7 days.
Renal: 70% unchanged; fecal: 30% (including metabolites).
Renal (estradiol: ~40-50% as glucuronide and sulfate conjugates; gestodene: ~30-40% as metabolites) and fecal (estradiol: ~20-30%; gestodene: ~30-40%). Less than 1% excreted unchanged.
Category C
Category C
Oral Contraceptive
Oral Contraceptive